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A B S T R A C T
Background and objectives: Conventional antibiotics select strongly for resistance and are consequently
losing efficacy worldwide. Extracellular quenching of shared virulence factors could represent a more
promising strategy because (i) it reduces the available routes to resistance (as extracellular action
precludes any mutations blocking a drug’s entry into cells or hastening its exit) and (ii) it weakens
selection for resistance, as fitness benefits to emergent mutants are diluted across all cells in a
cooperative collective. Here, we tested this hypothesis empirically.
Methodology: We used gallium to quench the iron-scavenging siderophores secreted and shared among
pathogenic Pseudomonas aeruginosa bacteria, and quantitatively monitored its effects on growth in vitro.
We assayed virulence in acute infections of caterpillar hosts (Galleria mellonella), and tracked resistance
emergence over time using experimental evolution.
Results: Gallium strongly inhibited bacterial growth in vitro, primarily via its siderophore quenching
activity. Moreover, bacterial siderophore production peaked at intermediate gallium concentrations,
indicating additional metabolic costs in this range. In vivo, gallium attenuated virulence and
growth—even more so than in infections with siderophore-deficient strains. Crucially, while resistance
soon evolved against conventional antibiotic treatments, gallium treatments retained their efficacy over
time.
Conclusions: Extracellular quenching of bacterial public goods could offer an effective and evolutionarily
robust control strategy.
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INTRODUCTION
Like all organisms, pathogens acquire genetic mu-
tations, and, in time, even ‘pure’ cultures will inevit-
ably come to harbor mutant lineages. Such genetic
variability can make some pathogen variants less
sensitive to therapeutic interventions than others,
and under strong or sustained therapy, these resist-
ant variants will have a selective advantage and will
come to predominate over more susceptible vari-
ants. Consequently, the therapy will lose efficacy [1,
2]. To avoid this situation, we can try to prevent re-
sistant variants from arising and/or from spreading
[3]. To prevent resistance arising, we could attempt
to reduce mutation supply, through limiting effect-
ive population size or by employing interventions
with specialized modes of action where relatively
few ‘routes to resistance’ are possible. To prevent
spread, meanwhile, we must aim to minimize fitness
differences across individual pathogens. Killing
every individual, the conventional antibiotic strat-
egy, could certainly quash fitness evenly, but this is
difficult in practice and whenever incomplete gives
resistant pathogens a strong relative fitness advan-
tage. ‘Antivirulence’ treatments, meanwhile, osten-
sibly disarm but do not harm pathogens, such that
resistant variants should benefit little relative to sus-
ceptibles [4]. However, traits that affect virulence but
not fitness are rare, and the label ‘antivirulence’ is
used liberally, even for interventions that yield sub-
stantial fitness differences among pathogens [4]. A
final way to minimize fitness differences is to tar-
get pathogens’ collective traits, where costs and
benefits are widely shared. For instance, many viru-
lence-related bacterial exoproducts are also public
goods (PGs) [5]. Under PG-quenching therapy, any
mutations allowing PGs to build up again should
benefit both resistant and susceptible individuals
alike, which would hinder the spread of resistance
[1, 6–8].
To illustrate why this matters, let’s consider a
specific example. Quorum quenching (QQ), which
disrupts the cell-to-cell communication [quorum
sensing (QS)] [9] underlying a wide range of collect-
ively expressed virulence traits, is a PG-targeting
‘antivirulence’ therapy regarded as a promising
alternative to conventional bacteriocidal or bacterio-
static treatments [10, 11]. However, early enthusi-
asm for QQ has been tempered recently by reports
that bacteria can quite readily evolve resistance to
such treatments [12–14]. Set against our framework,
this is unsurprising: first, QQ interventions
frequently involve intracellular action, against which
many potential resistance-conferring adaptations
could arise (e.g. modified membrane properties to
block a drug’s entry into a cell, or upregulated efflux
pumps to hasten its exit [15]). Second, QS regulates
not only PGs but also certain essential private goods
[16], giving QQ resistants substantial personal bene-
fits over susceptibles—and therefore a means to
spread. For maximal evolutionary robustness, we
need therapies where resistance mutations are un-
likely to arise in the first place (e.g. extracellular ac-
tion restricts potential routes to resistance) and are
also unlikely to spread, because fitness differences
between resistant and susceptible pathogens are
minimized. The latter should be the case when col-
lective traits are targeted, because fitness conse-
quences are shared across many individuals. Of
course, the extent and evenness of this sharing will
depend on the relatedness and spatial structure
of the pathogen population and the diffusive
properties of the environment, and these factors
would also need to be considered during therapy
design [3].
In this study, we investigate—in a test case—the
hypothesis that extracellular PG quenching is an
effective and evolutionarily robust strategy for patho-
gen control. The PG trait we target is siderophores,
important exoproducts whose regulation is not linked
to any exclusively private goods. Siderophores are dif-
fusible molecules with a high affinity for ferric iron
(Fe3þ) and are secreted by most bacteria to scavenge
this important but generally bio-unavailable form of
iron from their environment or, in the case of patho-
gens, from their host’s own iron-chelating com-
pounds [17]. Once loaded with Fe3þ, siderophores
are taken up by producer cells—or other nearby indi-
viduals equipped with appropriate receptors—
stripped of their iron, and secreted once again into
the environment [18]. Although their primary function
may be to scavenge iron, siderophores also bind, with
varying success, several other metals [19, 20]. Among
these, gallium is the closest mimic of iron. Ga3þ and
Fe3þ ions have very similar ionic radii and binding
propensities but, crucially, while Fe3þ reduces readily,
Ga3þ does not [19]. Ga3þ therefore cannot replace
iron as a co-factor in redox-dependent enzymes. We
investigated the iron-mimicking effects of gallium on
pyoverdine, the primary siderophore of Pseudomonas
aeruginosa [21], a widespread opportunistic pathogen
with a broad host range and, in humans, the cause of
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notoriously persistent infections in immune-
compromised tissues, cystic fibrosis lungs and in as-
sociation with implanted devices [22]. Pyoverdine,
which plays an important role in such infections [23,
24], binds gallium at least as readily as iron, and gal-
lium-bound pyoverdine is of no use to iron-starved
cells [19, 20]. Thus, even without entering the cell,
gallium can reduce P. aeruginosa growth and biofilm
formation by quenching local stocks of secreted
pyoverdine and choking off iron supply [19, 25].
Below, we report our investigations into (i)
gallium’s in vitro interference with siderophore-
mediated iron uptake and consequent effects on
bacterial growth, (ii) gallium’s in vivo effects on viru-
lence and in-host bacterial growth and (iii) the
potential for bacteria to evolve resistance against
gallium treatment.
METHODOLOGY
Strains and media
Pseudomonas aeruginosa strains featured in our
experiments included the wild-type strain PAO1
(ATCC 15692), the siderophore knock-out mutants
PAO1pvdD and PAO1pvdDpchEF [26], provided
by P. Cornelis, Free University of Brussels, Belgium, as
well as versions of the above strains constitutively ex-
pressing GFP (PAO1-gfp, PAO1pvdD-gfp, chromo-
somal insertion: attTn7::ptac-gfp), and a version of
PAO1 with a pvdA-gfp reporter fusion (PAO1pvdA-gfp,
chromosomal insertion: attB::pvdA-gfp) [27], provided
by P. K. Singh, University of Washington, USA. We also
used the Rhl-quorum-sensing deficient mutant
PAO1rhlR, provided by S. P. Diggle, University of
Nottingham, UK. For overnight culturing, we used
Luria Bertani (LB) medium, while for experimental
assays we used CAA medium, supplemented with
FeCl3 where indicated to manipulate iron availability.
LB was obtained pre-mixed from Sigma-Aldrich,
Switzerland. Our standard CAA medium contained
5 g l1 casamino acids, 1.18 g l1 K2HPO4*3H2O,
0.25 g l1 MgSO4*7H2O, 100mg ml
1 human-apo
transferrin, 20 mM NaHCO3 and 25 mM HEPES buffer
(all from Sigma-Aldrich).
In vitro assays of growth and pyoverdine
production
Overnight LB cultures (37C, 180 rpm), washed and
standardized for cell density, were diluted to 104
then used to seed replicate cultures in CAA medium
supplemented with Ga(NO3)3 (such that final Ga
concentrations ranged from 0 to 200mM), as
well as complementary amounts of NaNO3 to bal-
ance nitrate levels across treatments, and 20 mM
FeCl3 where iron-replete conditions were required
(Fig. 1A). Growth assays were performed with 200ml
cultures in 96-well plates, for which optical density
(OD) was tracked over 24 h at 37C using a Tecan
Infinite M-200 plate reader (Tecan Group Ltd.,
Switzerland), with 15 min read intervals preceded
at each read by 10 s of agitation. To assay pyoverdine
production, we first grew PAO1pvdA-gfp in 2 ml CAA
static in 24-well plates in a 37C incubator for 24 h,
then centrifuged the cultures at 7000 rpm for 2 min
to pellet the cells. From each culture, 200 ml of super-
natant and, separately, the cell fraction resuspended
in 200ml 0.8% saline, were transferred to a new 96-
well plate and assayed for OD at 600 nm and fluor-
escence (GFP in cell fraction: exjem¼ 488j520 nm;
pyoverdine in supernatant: 400j460 nm) [28]. Both
fluorescence measures were standardized by OD
at 600 nm. In a series of side experiments, we
investigated potential biases associated with the
use of optical measures as proxies for pyoverdine
production (Supplementary Fig. S1). Data pre-
sented in Fig. 1B are corrected for these biases.
Experimental infections
Infection assays were performed with final instar
Galleria mellonella larvae, purchased from a local
supplier, standardized for mass and general condi-
tion and stored at 4C until use (within 3 days).
A Hamilton precision syringe was used to deliver
10ml inocula via a sterile 26s gauge needle
introduced sub-dermally to a surface-sterilized area
between the last pair of prolegs. Inoculations con-
tained Ga(NO3)3 diluted to different concentrations
in 0.8% saline, with complementary concentrations
of NaNO3, and, where specified, bacteria from over-
night LB cultures (37C, 180 rpm), standardized for
cell density and diluted such that each 10 ml inocula
contained 25 CFU (post hoc counts of 12 inocula
plated out to LB agar gave 95% CI of 19.41–31.76).
Specifically, we tested the following Ga(NO3)3 con-
centrations: 2.5, 10 and 50 mM (‘LOW’; pooled to-
gether since their resulting virulence curves were not
significantly different from one another), 500 mM
(‘MED’) and 2500 mM (‘HIGH’). Our ‘Gallium only’
treatment comprised various concentrations be-
tween 2.5 and 2500mM, which again we pooled
for statistical analyses because of similar effects
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on survival. Post-injection, larvae were placed indi-
vidually in randomly allocated wells of 24-well plates
and incubated at 37C. Survival was monitored
hourly between 10 and 24 h, and larvae were con-
sidered dead once they no longer responded to tact-
ile stimulation. Any larvae that began to pupate while
under observation or died within the first 10 h post-
injection (i.e. as a result of handling) were excluded
from analyses (n¼ 23, 3.6%). To assay in vivo bac-
terial growth, we prepared our inocula with strains
engineered to constitutively express GFP (see
above), having previously established that constitu-
tively expressed GFP signal could provide a reliable
correlate of bacterial density under the conditions
of this infection model (Supplementary Fig. S2). In
each of six separate experimental blocks, and at each
of four discrete timepoints, 3–4 randomly selected
larvae per treatment were flash-frozen in liquid N2
and manually powderized. Powdered larval hom-
ogenates were resuspended in 1 ml sterile H2O, vig-
orously shaken and then centrifuged at 7000 rpm for
2 min, whereafter the sample segregated into dis-
crete phases. About 200 ml of the water-soluble
liquid phase was extracted and assayed for GFP-
fluorescent signal relative to control replicates (sa-
line-injected larvae), using a Tecan Infinite M-200
plate reader. Given total larval volumes of 1 ml,
and assuming that 20% of this volume might be
hemolymph accessible to particles diffusing from a
single injection site during the course of an acute
infection, we estimate that inocula gallium concen-
trations of 2.5–2500mM would translate to in-host
gallium concentrations of roughly0.05 to50 mM.
Experimental evolution
We compared the growth inhibitory effects of gal-
lium versus the aminoglycoside, gentamicin (Gm),
and the fluoroquinolone, ciprofloxacin (Cp)—two of
several antibiotics recommended for clinical use
against P. aeruginosa [29]. Concentrations were
calibrated such that they reduced growth integrals
over the initial 24 h to 1/3 that of untreated PAO1
WT cultures under the same growth conditions.
For each of 12 days, a 96-well plate was prepared,
comprising replicate 198ml volumes of iron-limited
CAA medium supplemented, according to a
randomized layout scheme, with gallium, antibiotics
or an equivalent volume of saline (see key in Fig. 3 for
details of treatments used and their respective sam-
ple sizes). Day 1 cultures were initiated with 2ml ali-
quots of a 103 diluted overnight LB culture of PAO1
WT (37C, 180 rpm), while for subsequent days,
fresh plates were inoculated with 10 ml of undiluted
culture from the corresponding wells of the previous
day’s plate, directly after it completed its growth
cycle. Plates were incubated at 37C, and cell density
and pyoverdine fluorescence measures were re-
corded at 15 min intervals (with 10 s initial shaking)
using a Tecan Infinite M-200 plate reader.
Figure 1. Gallium affects P. aeruginosa’s in vitro growth and siderophore production. (A) Gallium suppresses growth particularly when pyoverdine is present, as
shown here by comparing conditions with and without its production. Symbols and bars indicate means and 95% CIs of integrals of spline curves fitted through
24 h growth trajectories (OD at 600 nm) of 12 replicate cultures. (B) Pyoverdine, assayed using complementary approaches, is in each case upregulated at
intermediate gallium concentrations. Symbols and error bars represent means and SEs of five replicates. Measures of pyoverdine from supernatant (filled circles)
or pvdA expression from cell fractions (open circles) are in each case scaled by cell density (OD at 600 nm).
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Endpoint phenotypic assays
Prior observations [30] and our own reasoning (see
Table 1) suggested that pyoverdine and pyocyanin
could both affect the costs and benefits of iron
uptake under gallium treatment. Anticipating that
the experimental evolution described above might
have induced changes in these traits, we performed
phenotypic assays to compare cultures of our ances-
tral PAO1 WT, its descendent lines experimentally
evolved in CAA with or without supplementa-
tion with 20 mM Ga, and also two knock-out mu-
tant strains which served as negative controls:
PAO1pvdD (deficient for pyoverdine production)
and PAO1rhlR (deficient for the Rhl-quorum-
sensing system which regulates pyocyanin produc-
tion [31]). Specifically, we inoculated 2 ml volumes of
growth medium (either LB or CAA) with 20ml of 103
diluted overnight LB culture and incubated at 37C
in static conditions. After 24 h, we measured OD
600, centrifuged at 7000 rpm for 2 min, then ex-
tracted 200ml aliquots of supernatant and assayed
these for growth (OD at 600 nm) and levels of
pyocyanin (using OD at 691 nm) [32] and pyoverdine
(fluorescence at 400j460 nm), using a Tecan Infinite
M-200 plate reader.
Statistical analyses
All analyses were performed using R 3.0.0 [33].
Spline curves were fitted to time course growth data
using the ‘grofit’ package [34]. Survival analyses were
performed using the Surv package [35]. Although in
the main text we compared survival curves using
parametric Weibull models, we also repeated all ana-
lyses using Cox proportional hazards regressions,
and obtained qualitatively comparable results in all
cases.
RESULTS
In in vitro assays, we found that gallium strongly in-
hibited bacterial growth, and that the inhibitory ef-
fects were mediated primarily via gallium’s
extracellular quenching activity and not because gal-
lium is toxic per se (Fig. 1A). When siderophores
were required and could be produced, increasing
gallium concentration was associated with a steep
decline in growth (slope ± SE of regression with
log10[Ga]: 0.435 ± 0.011, t¼38.04, P< 0.001).
In contrast, when siderophores were not required
and not produced, gallium only weakly affected
growth (slope ± SE: 0.067 ± 0.019, 95% CI for
drop¼ [2.91–15.86%]; difference in slopes
0.368 ± 0.022, F1,140¼ 276.41, P< 0.001)—particu-
larly over the range of concentrations up to and
including 50 mM, which correspond to the concen-
trations likely experienced in our in vivo experiments
(see below).
It has been suggested that as the benefit of
pyoverdine production drops, bacteria should grad-
ually scale back their investment in this trait [19].
On the other hand, it has also been shown that
pyoverdine production is upregulated in response
to more stringent iron limitation [28], as presumably
induced by gallium. Here, we saw a combination of
these two regulatory effects, with investment to re-
place quenched pyoverdine actually increasing from
low to intermediate gallium supplementation levels
and cessation becoming evident only at higher con-
centrations (Fig. 1B; ANOVA comparison of quad-
ratic versus linear fits: F1,36> 15, P< 0.001 in
each case).
Given our in vitro observations of gallium’s effects
on growth and pyoverdine production, we expected
it to affect virulence and bacterial fitness in vivo too.
We tested this in experimental infections of greater
waxmoth larvae (G. mellonella). Gallium-supple-
mented P. aeruginosa infections indeed showed sig-
nificantly attenuated virulence compared with non-
supplemented infections (Fig. 2A–C; Weibull curve
comparison: z¼ 3.10–7.82, P< 0.001 in all cases).
Notably, infections supplemented with medium and
high concentrations of gallium (corresponding to
the intermediate gallium concentration used in the
in vitro assays, see ‘Methodology’ section) were sig-
nificantly less virulent (z¼ 4.96 and 2.39, P< 0.05 in
both cases) than infections with PAO1pvdD, a mu-
tant defective for pyoverdine production that itself
showed attenuated virulence versus PAO1 (z¼ 3.49,
P< 0.001). Gallium alone appeared to have little ef-
fect on hosts, with levels of virulence not signifi-
cantly different from those seen in saline-injected
controls (Fig. 2A: survival curve comparison:
z¼0.93, P¼ 0.35; Fig. 2B: pairwise proportion
tests for survival rates: X21 ¼ 0.43, P¼ 0.51).
Bacterial growth in vivo was also significantly
reduced by gallium (Fig. 2D and E). Growth integrals
were lower in gallium-supplemented larvae than in
WT-injected larvae (Fig. 2E; Tukey’s 95% CIs for the
difference: 16.21–21.44%, t¼ 17.24, P< 0.001) and,
moreover, lower than in larvae injected with the sid-
erophore-defective mutant, PA01pvdD (Fig. 2E;
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Tukey’s 95% CI¼ 13.58–18.97%, t¼ 14.45,
P< 0.001).
To investigate empirically the general potential
for resistance against gallium, we performed
experimental evolution with serial batch cultures,
comparing P. aeruginosa exposed to gallium ver-
sus several single- and mixed-antibiotic regimes
(Fig. 3A–E). At first, all treatments were strongly re-
fractory to growth, showing 24 h growth integrals no
more than a third those of untreated controls (range:
5.8–32.3%). Over the course of a 12-day experiment
(a therapy duration that matches clinical standards),
however, the growth in all antibiotic treatments
increased significantly (Fig. 3E; H0 slopes¼ 0: Cp1:
t¼ 5.54, Cp2: t¼ 3.86, Gm1: t¼ 5.43, Gm2: t¼ 9.12,
Mix1: t¼ 5.26, Mix2: t¼ 7.02; P< 0.001 in each
case), and by the final timepoint their growth inte-
grals were comparable to those of the untreated con-
trols at the start of the experiment (Fig. 3A–D).
Gallium-treated cultures, meanwhile, like the
untreated control, did not show a significant trend
toward higher growth (Fig. 3E; H0 slopes¼ 0;
t¼0.30,P¼ 0.76; t¼ 1.60,P¼ 0.11 and t¼0.11,
P¼ 0.91 for control, Ga1 and Ga2, respectively).
Per-capita pyoverdine output was generally
steady over the course of experimental evolution
[Supplementary Fig. S3: H0 slopes¼ 0: control:
z¼ 0.56, P¼ 0.58; Ga1: z¼ 0.45, P¼ 0.65; all antibi-
otic treatments pooled (Day 1 excluded): z¼ 0.83,
P¼ 0.41], with that of the 20 mM gallium treatment
consistently around 2-fold higher than either control
or antibiotic-treated cultures (95% CIs for fold-
difference were 1.86–2.13 versus control, and
1.96–2.24 versus pooled antibiotic treatments).
In the endpoint phenotypic assays performed
under standardized test conditions (CAA and
LB media), lines evolved in the Ga1 treatment
showed no significant change in pyoverdine produc-
tion (Fig. 4A) relative to their ancestor (CAA:
t¼ 0.81, P¼ 0.43; LB: t¼ 0.08, P¼ 0.94) or to lines
evolved under control conditions (CAA: t¼0.49,
P¼ 0.63; LB: t¼ 0.95, P¼ 0.36), suggesting that the
Figure 2. Gallium attenuates P. aeruginosa virulence and growth in G. mellonella larvae. (A–C) Virulence across treatments, as
Kaplan–Meier (stepped lines) and Weibull (smoothed lines) survival curves; proportion surviving (with 95% binomial CIs); and
time-to-death (means and 95% CIs). We estimate that inocula with ‘LOW’ (2.5–50 mM), ‘MED’ (500mM) or ‘HIGH’ (2500 mM)
concentrations of Ga(NO3)3 gave in-host concentrations of0.05 to50 mM (see ‘Methodology’ section). (D) Bacterial density
in vivo (GFP signal in host homogenate; means and 95% CIs from 24 larvae) corrected against saline-injected controls and
scaled relative to PAO1 at 13 h. (E) Mean and 95% CIs of bacterial growth integrals derived from bootstrap replicate time series
(24 replicate splines) from (D)
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high pyoverdine output seen during experimental
evolution was predominantly a plastic response to
gallium (see Fig. 1B). In contrast, the production of
pyocyanin did appear to be elevated in the Ga1
endpoint isolates (Fig. 4B) in CAA medium (ver-
sus ancestor: t¼ 3.40, P¼ 0.004; versus control:
t¼ 3.09, P¼ 0.008) but not in LB medium (versus
ancestor: t¼ 1.69, P¼ 0.12; versus control: t¼ 1.56,
P¼ 0.15).
DISCUSSION
The results reported above indicate that gallium in-
hibits P. aeruginosa growth primarily through extra-
cellular interference with its primary siderophore,
pyoverdine (Fig. 1A); that this growth inhibition
occurs in an infection context too (Fig. 2D and E),
along with a significant reduction in virulence
(Fig. 2A–C); and that resistance to gallium treat-
ments does not evolve easily—at least not in com-
parison to two conventional antibiotics we tested
(Fig. 3).
For gallium to be both optimally effective and
evolutionarily robust as an antibacterial agent, an
appropriately calibrated dose will be key. At lower
concentrations, efficacy should initially increase
with dose, but at too high concentrations, gallium
may increasingly transit across the cell membrane
and begin to interfere directly with iron metabolism,
causing general toxicity to bacteria and host cells
alike (Fig. 1A; [36]). Here, fitness costs are imposed
intracellularly at the individual cell level, and not
extracellularly at the level of the collective, which
would take us back to a classic antibiotic scenario,
with more potential ‘routes to resistance’ and
greater potential for steep fitness gradients among
individual cells. At sub-toxic levels, meanwhile,
where gallium acts primarily through siderophore-
quenching, resistance should evolve less readily.
Furthermore, we saw that the costs and benefits of
siderophore investment itself are also non-linear
functions of gallium concentration, owing to the ex-
istence of a regulatory ‘trap’. Specifically, intermedi-
ate concentrations of gallium induced the highest
levels of replacement pyoverdine production in bac-
teria (Fig. 1B), adding further metabolic stress to
increasingly iron-limited cells. Our in vivo results,
which showed that gallium can suppress virulence
to levels beyond those seen in pyoverdine-deficient
strains (Fig. 2A–C), are consistent with the interpret-
ation that an appropriate dose of gallium not only
restricts bacterial iron uptake but can also impose a
costly metabolic burden. Given our understanding
of the regulation of pyoverdine production, this
Figure 3. Evolutionary potential for resistance against gallium treatment. (A–D) Over the course of experimental evolution, daily
growth integrals for cultures treated with various antibiotics rose significantly, while the growth of gallium treated cultures did
not. (E) Slope coefficients for linear fits through data in (A–D), expressed as % of growth of control at Day 1. In all cases, symbols
and error bars show means and 95% CIs of six replicate cultures
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hump-shaped association between pyoverdine in-
vestment and gallium is to be expected. Positive
feedback occurs when incoming Fe3þ-bound sidero-
phores act via the receptor FpvA and the anti-sigma
factor FpvR to activate membrane-bound iron-star-
vation sigma factor PvdS [37]. High cytoplasmic
Fe2þ levels, meanwhile, can generate negative feed-
back. In this case, the Fe2þ induces Fur (ferric uptake
regulator)-mediated repression of pvdS [38]. At low
gallium concentrations, iron uptake into the cell is
steady, so negative feedback keeps pyoverdine
production at some intermediate level, while at
mid-range gallium concentrations, iron uptake be-
comes increasingly restricted, leading to steady
positive feedback, but weaker negative feedback,
and consequently, pyoverdine production increases.
Finally, at high concentrations, iron uptake may be
so severely restricted that the positive feedback loop
fails, and pyoverdine production stalls completely.
Exploiting metabolic ‘traps’ such as this could sig-
nificantly increase the effectiveness of treatments,
but requires that the associated regulatory networks
should be left intact and functional. This raises
another point in favor of extracellular quenching
strategies, as opposed to, say, intracellular-
mediated deactivation of entire molecular pathways.
To what extent should gallium’s antibacterial ac-
tivity be evolutionarily robust? In our selection ex-
periment (Figs 3 and 4A), we saw little evidence of
adaptation to gallium, although perhaps we can still
predict what sort of phenotypic changes could
conceivably confer resistance against gallium-
mediated siderophore quenching, and under which
conditions such adaptions could spread. Below, we
consider several potential evolutionary responses,
which are discussed further in Table 1.
First, let’s consider pyoverdine loss-of-function
mutants, which are known to arise readily under iron
limited conditions [39–41]. In co-infection with sid-
erophore producers, non-producing mutants could
act as cheats—no longer investing in the PG
yet still benefiting from the investment of nearby an-
cestors [5]. Even as opportunities to cheat dwindled,
such mutants could continue to spread, since,
disadvantaged as they would be with respect to
autonomous iron acquisition, they would at the same
time be freed of the substantial extra metabolic bur-
den of pyoverdine production under gallium regimes
(see Fig. 1B). Depending on specific conditions
within host tissues, the net fitness of non-producers
could be not far off that of pyoverdine producers
(Fig. 2E), so the mutants could potentially come to
occupy a substantial share of the population. We saw
no significant change in mean pyoverdine production
in strains evolved under gallium (Fig. 4A), suggesting
that cheats did not gain prominence in these cultures.
However, certain individual lines (three antibiotic
lines and one Ga1 line) went extinct during the course
of the experimental evolution, and this extinction
was in each case accompanied by a crash in per cap-
ita pyoverdine production levels (Supplementary
Fig. S3), which would be consistent with a scenario
Figure 4. Resistance-related phenotypic changes following experimental evolution under gallium treatment. Pyoverdine (A) and pyocyanin (B) production under
standardized test conditions (dark bars¼ LB medium, light bars¼CAA medium) of ancestral PAO1, knock-out strains (i.e. negative controls), control lines
(evolved without gallium) and gallium-selected lines. Pyoverdine measures are scaled to that of PAO1 in CAA, whereas pyocyanin is scaled to that of PAO1 in LB.
Asterisks indicate cases where Ga-selected lines were significantly different from their ancestor and unexposed control lines. Error bars give 95% CIs of
3–6 replicates
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Table 1. How likely is resistance against gallium-mediated pyoverdine quenching?
Mutant phenotype Why resistant? Likelihood for mutant to arise Likelihood for mutant to spread
Pyoverdine production
reduced or shut down.
No true resistance, as virulence
is only partly restored.
However, mutants could avoid
being ‘trapped’ into high
pyoverdine production
(Fig. 1B), which can be a
substantial fitness drain
(Fig. 2E).
High Low
Pyoverdine-negative mutants arise
readily [39, 41].
In mixed cultures, gallium re-
duces total population density
and the effective group size at
which pyoverdine can be
shared, and these effects both
disfavor the mutant [45, 46].
Pyoverdine modified to
bind iron with greater
specificity.
Iron uptake efficiency, and
hence growth, should
improve.
Low
(a) Pyoverdine has already
evolved high iron specificity
[20]. Further improvements
are unlikely.
(b) Ga3þ and Fe3þ remain
fundamentally very similar in
binding behavior.
Low
(a) Pyoverdine molecules are
shared across the local com-
munity [47], so producers of
the novel and the ancestral
pyoverdine types would benefit
similarly.
Regulatory shift from
producing pyoverdine to
producing pyochelin, a
secondary siderophore
normally deployed in less
iron-limited conditions.
Although pyochelin is generally
a less effective siderophore
than pyoverdine, this strategy
could be advantageous under
extreme conditions (e.g. in
the presence of gallium).
High Low
(a) Like pyoverdine, pyochelin is
also a shared trait, so benefits
would go to non-mutants too.
(b) Gallium can quench pyochelin
too, and so it still inhibits iron
uptake [49].
Regulatory mechanisms already
exist to facilitate facultative
switching between siderophore
types in response to changing
iron stress [48]. Mutations
that alter this switch could
probably arise easily.
Own pyoverdine production
reducedþ specialization
to use heterologous
siderophores from other
co-infecting species.
Ceasing pyoverdine production
would reduce personal costs,
and heterologous sidero-
phores could offer
compensatory benefits.
Low Low
(a) Most siderophores (e.g.
desferrioxamine) are still prone
to bind gallium [51].
(b) Wild-type P. aeruginosa can
also facultatively switch to
heterologous siderophore use
whenever such siderophores
become available [50].
Although P. aeruginosa can al-
ready take up heterologous
siderophores (e.g.
enterobactin, desferrioxamine)
[50], this route would require
co-infection with a bacterium
that produces an accessible
siderophore.
Own pyoverdine production
reducedþ specialization
to take up iron directly
from the host.
Ceasing pyoverdine production
would reduce personal costs,
while iron from other sources
could offer compensatory
benefits.
High Low
(a) Some host iron chelators
might also bind gallium (e.g.
citrate).
(b) Wild-type P. aeruginosa can
also facultatively switch to al-
ternative uptake mechanisms
when such sources become
available [50].
P. aeruginosa already possesses
the means to take up iron in
various forms [50], including
when it is in complex with
hosts’ iron chelators. A simple
switch in a regulatory pathway
might be all that is required.
Upregulated production of
reducing agents
(e.g. pyocyanin), which
extracellularly reduce
ferric to ferrous iron.
Reducing agents increase avail-
ability of the more soluble
ferrous form of iron (Fe2þ),
which can be taken up with-
out the need for siderophores.
High Low
(a) Increased production of a me-
tabolite would induce extra
costs.
(b) Like pyoverdine, pyocyanin is
also a shared trait, so benefits
(in the form of ferrous iron)
would go to non-mutants too.
Upregulation of an already
existing trait could be
achieved easily [30].
Here, we consider various mutant phenotypes that could putatively confer resistance, and propose hypotheses regarding the likelihood of emergence
and spread in each case.
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of siderophore-non-producing cheats spreading
in these cultures. In any event, the rise of such
mutants should still lead to less virulent infections
(Fig. 2A–C; [42–44]).
Alternative scenarios for evolutionary responses
to gallium treatment could involve modifying
pyoverdine to have substantially greater affinity
for Fe3þ than for Ga3þ, or switching to ‘backup’ sid-
erophores relatively less susceptible to gallium
(Table 1). Such mutations could conceivably arise
but in each scenario we would expect attendant
selection for the mutation to be relatively weak be-
cause, as PGs, these alternative or modified sidero-
phores’ benefits would still be accessible to all cells
within diffusion range, including those lacking the
novel mutation. In addition, gallium and iron remain
fundamentally similar in their physical properties,
such that gallium will still bind—to some extent at
least—any modified siderophore.
Further possible evolutionary responses could
involve mutants that specialize in the direct uptake
of Fe3þ-containing compounds produced by other
competing microbes (i.e. inter-specific cheats),
or present as chelators in the host tissues. Such mu-
tations are also conceivable, given that bacteria al-
ready possess a diversity of iron-uptake machineries
[50]. However, considering that gallium can displace
Fe3þ from other compounds too, it is not clear that
such strategies would offer any clear advantages
over siderophore-mediated uptake.
Finally, bacteria could potentially sidestep their
dependence on the Fe3þ form of iron (prevalent
under oxygen replete and neutral pH conditions)
by altering their environment to increase the extra-
cellular availability of the more bio-available Fe2þ
ions. Indeed, overproducers of pyocyanin, a redox-
active metabolite, have recently been reported to be
refractory to gallium [30], and in our own experi-
ments, we did see a weak but significant mean
increase in pyocyanin production under certain
conditions among cultures evolved under gallium
treatment (Fig. 4B). However, such metabolites
are themselves PGs, so the spread of over-producers
could be constrained in due course by the free-
loading behavior of variants that produce less, yet
still benefit by the increased availability of Fe2þ ions.
In our experimental infections, we observed that
gallium supplementation reduced both the virulence
and the in-host fitness of P. aeruginosa (Fig. 2).
However, pathogen fitness and virulence will not
always be strongly positively correlated [43, 52].
For example, we showed that intermediate gallium
induced overexpression of pyoverdine (Fig. 1B), and
in some contexts, this could potentially lead to
higher virulence, given that pyoverdine production
is linked to certain other virulence factors [53, 54].
Indeed, while gallium is generally known to reduce
virulence [19], one recent study [55] showed that in
very dense cultures, gallium supplementation actu-
ally upregulated production of certain virulence fac-
tors. Thus, while gallium represents a promising way
to reduce bacterial load, its overall effectiveness in
reducing damage to a host will, as always, depend
also on the particular characteristics of the host and
its interaction with the pathogen.
CONCLUSIONS AND IMPLICATIONS
Gallium has seen application in medical contexts for
years (e.g. as an anti-cancer drug [56]) and has pre-
viously been proposed, and tested, as a treatment
against bacterial infections [19, 25, 57, 58]. Gallium
can be directly toxic at high concentrations, but here,
working with concentrations below this toxic
range, we have focused on its capacity to indir-
ectly affect bacteria through disruption of sidero-
phore-mediated iron uptake. Specifically, gallium
quenches siderophores extracellularly, starving cells
of iron and pushing them into a metabolically costly
regulatory trap from which there seems to be little
scope for evolutionary escape. In light of our results,
we contend that this approach—and more generally
the extracellular targeting of PGs—could curb mi-
crobial virulence in an evolutionarily robust manner,
and therefore represents a promising alternative to
our dwindling succession of traditional antibiotics
[59–61].
supplementary data
Supplementary data are available at EMPH online and at the
Dryad depository: doi:10.5061/dryad.8kk36.
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